Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Drug safety requirements vary across regions, making consistent reporting a complex task for global teams. This article explains key regulatory expectations, ICH guidelines, ICSR reporting, MedDRA terminology, and practical considerations for maintaining compliant safety reporting worldwide.
Learn how pharmacovigilance teams evaluate suspected adverse drug reactions using structured approaches, including WHO UMC causality assessment, Naranjo scale principles, and clinical evidence review. Discover how temporal relationship, dechallenge, rechallenge, and alternative causes influence safety decisions.
Understand how PSUR, PBRER, and DSUR support safety oversight across the product lifecycle. This guide explains reporting timelines, data lock points, reconciliation controls, benefit-risk assessment, and inspection expectations to help pharmacovigilance teams strengthen compliance and reporting quality.
Understand how GVP modules shape pharmacovigilance systems, inspections, QPPV oversight, audits, risk management, and signal activities. This guide explains what regulators expect, which records matter most, and how PV teams can maintain practical, inspection-ready compliance.
Effective drug safety depends on choosing the right monitoring approach. This article explains active and passive systems, spontaneous reporting, targeted follow-up, and post-marketing studies, while showing how each method supports signal detection, compliance, and inspection readiness.
Explore how drug safety teams manage ICSRs, signals, risks, inspections, and regulatory responsibilities. This article also explains key pharmacovigilance jobs, required skills, career progression, and the evidence companies need to maintain strong compliance.
Explore how the pharmaceutical supply chain connects GDP controls, cold-chain logistics, serialization, supplier oversight, and shortage prevention. Learn practical strategies to strengthen traceability, reduce distribution risks, and build more resilient, compliant pharmaceutical logistics operations across global networks today.
Pharmaceutical teams face growing pressure to strengthen quality systems, CAPA, and inspection readiness. This article explains where external expertise adds value, how consultants support remediation, and what evidence regulators expect from a resilient, inspection-ready pharmaceutical quality system.
India’s pharmaceutical regulatory system is evolving through stronger CDSCO regulations, revised Schedule M requirements, risk-based inspections, and updated approval controls. This guide explains the key laws, authorities, licensing requirements, and compliance expectations pharmaceutical professionals need to understand in 2026.
Explore how EU pharmaceutical legislation reform, EMA regulatory requirements, marketing authorisation, and EU GMP expectations are reshaping pharmaceutical compliance. This article explains the legal framework, post-approval variations, manufacturing controls, inspection readiness, and the key changes companies should monitor.